The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global peptide therapeutics market reached a value of US$ XX Billion in 2020. Looking forward, IMARC Group expects the market to grow at a CAGR of XX% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Peptides are efficacious and selective signaling molecules that bind to specific cell surface receptors, such as ion channels and G protein-coupled receptors (GPCRs) and trigger intracellular effects. They are employed in the pharmaceutical industry to design novel regenerative therapeutics that can target a wide range of cells and manipulate their responses. These therapeutics are less toxic, relatively safe, and well-tolerated than other treatment options. As a result, they are gaining traction in clinical practices worldwide to manage cancer, injuries, infectious diseases, metabolic disorders, and aesthetic concerns.
The growing prevalence of acute and chronic diseases, along with the rising access to medical facilities, represents one of the leading factors positively influencing the demand for peptides to develop innovative therapies. Moreover, peptides therapies are used in cosmeceutical surgeries to slow down the process of skin aging. This, coupled with the increasing consciousness among individuals about physical appearance and the desire to retain young and healthy skin, is driving the adoption of cosmetic surgeries and peptide therapeutics around the world. Apart from this, with the introduction of novel synthetic strategies that reduce injection frequency and improve stability and other physical properties, peptide therapeutics are widely being used in injections for diabetic patients. This, in confluence with the increasing incidence of diabetes and the growing preference for quick and precise treatment methods, is influencing the use of peptide therapeutics over oral medications. Furthermore, the emerging trend of personalized and targeted treatments is catalyzing the demand for multifunctional peptide-based materials. This, along with the rising funding to develop novel peptide therapeutics for treating autoimmune and inflammatory diseases, is projected to create a positive market outlook.
IMARC Group provides an analysis of the key trends in each sub-segment of the global peptide therapeutics market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on type, type of manufacturer, synthesis technology, routes of administration and application.
Breakup by Type:
Breakup by Type of Manufacturer:
Breakup by Synthesis Technology:
Breakup by Routes of Administration:
Breakup by Application:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Amgen Inc., Apitope International NV, Arch Biopartners Inc., AstraZeneca plc, Circle Pharma Inc., Corden Pharma GmbH, F. Hoffmann-La Roche AG, Ipsen Group, Lonza Group AG, Novo Nordisk A/S, Pfizer Inc., Teva Pharmaceuticals Industries Ltd. and Zealand Pharma A/S.
|Base Year of the Analysis||2020|
|Segment Coverage||Type, Type of Manufacturer, Synthesis Technology, Routes of Administration, Application, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Amgen Inc., Apitope International NV, Arch Biopartners Inc., AstraZeneca plc, Circle Pharma Inc., Corden Pharma GmbH, F. Hoffmann-La Roche AG, Ipsen Group, Lonza Group AG, Novo Nordisk A/S, Pfizer Inc., Teva Pharmaceuticals Industries Ltd. and Zealand Pharma A/S.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2299
Five User License: US$ 3399
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at